Anecova is a life science company focused on the development and commercialization of new technologies in the field of Assisted Reproductive Technologies (ART). Our goal is to improve the overall quality of care in ART by enabling the use of more physiologic and natural processes.
The first Anecova product aims to restore the fertilization and early development of the embryo to the natural environment of the maternal womb. This technology enables the embryos to start their life in close communication with the maternal environment. This is expected to increase the number of high-quality embryos and improve the success rate of the assisted reproductive cycle.
The preliminary results are encouraging. We are therefore undertaking further clinical evaluation, in close collaboration with international experts in the field, with the goal of improving the experience of assisted reproduction for patients around the world.